New data to support edoxaban in patients with atrial fibrillation undergoing cardioversion

Results from the global phase 3b ENSURE-AF study of 2,199 patients with non-valvular atrial fibrillation (NVAF) undergoing electrical cardioversion were presented recently at the ESC Congress 2016 in Rome, and published online in The Lancet. The study demonstrated that oral, once-daily edoxaban (Lixiana) met the study’s primary endpoints, demonstrating comparable efficacy and safety to well-managed enoxaparin/warfarin (mean time in therapeutic range on warfarin was 70.8%) for the prevention of stroke and other blood clot complications.  ENSURE-AF is a PROBE parallel group study designed to evaluate the efficacy and safety of once-daily edoxaban versus enoxaparin/well-managed warfarin in patients with NVAF undergoing electrical cardioversion.